- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Post Conference Perspectives: ASH 2024 : Episode 3
Exploring Combination Therapy with Ibrutinib and Rituximab in cGVHD
Sergio A. Giralt, MD, discusses how rituximab plays a key role in treating chronic graft-vs-host disease. It is often used in combination with ibrutinib to enhance therapeutic outcomes. He reviews the study design and efficacy and safety data from recent trials and discusses how these results will influence his clinical practice moving forward.
Video Player is loading.
EP: 1.The Pathophysiology of Chronic Graft-Vs -Host Disease (cGVHD) and the Role of CSF1R
EP: 2.Examining Axatilimab in the AGAVE-201 Trial For cGVHD
Now Viewing
EP: 3.Exploring Combination Therapy with Ibrutinib and Rituximab in cGVHD
EP: 4.Discussing Real-World Ruxolitinib and Corticosteroid Treatment Patterns in Patients with cGVHD
EP: 5.The Role of Posttransplant Cyclophosphamide in Patients With cGVHD
EP: 6.Main Conference Takeaways Regarding cGVHD Management
Video content above is prompted by the following:
- What is the role of rituximab in your clinical practice in patients with chronic graft-vs-host disease?
- Do you ever use rituximab in combination with ibrutinib?
- What were the study design and methods of this abstract?
- What were the key efficacy and safety results seen in this abstract?
- Will these results impact your clinical practice going forward?
Related Videos
Understanding the Hesitancy to Prescribe Amyloid-Targeting Therapies for Patients With Alzheimer Disease
The Metro Nashville Public Schools Initiative
Recurrence Rates in Uncomplicated UTIs
Patient Selection for Amyloid-Targeting Therapies: Key Characteristics and Considerations
Adoption Strategies
Patient Factors Influencing Antibiotic Selection in Uncomplicated UTIs
Diagnosing IgA Nephropathy
A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk
AAD 2025 Insights: Treatment Patterns in Moderate to Severe Psoriasis Patients on Biologics
How the Genetic Nature of Lp(a) Levels Influences Screening
Related Content
ICYMI: Highlights From AMCP Nexus 2024
December 26th 2024Article
Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting, which included relevant topics in health care policy, novel pharmaceutical developments, financial considerations across multiple conditions, and more.
Read More
